With Selpercatinib and Pralsetinib, two RET-inhibitors are now available for patients with RET-altered thyroid or lung cancer (Drilon et al. 2020; Wirth et al. 2020; Subbiah et al. 2021). Here, RET is linked to thyroid gland disorder.